title: Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation.
abstract: Two genetic loci selected for norfloxacin (nfxB) and ciprofloxacin (cfxB) resistance were characterized. Both mutations have previously been shown to confer pleiotropic resistance to quinolones, chloramphenicol, and tetracycline and to decrease expression of porin outer-membrane protein OmpF. nfxB was shown to map at about 19 min and thus to be genetically distinct from ompF (21 min), and cfxB was shown to be very closely linked to marA (34 min). cfxB was dominant over cfxB+ in merodiploids, in contrast to other quinolone resistance mutations. The two loci appear to interact functionally, because nfxB was not expressed in the presence of marA::Tn5. Both nfxB and cfxB decreased the expression of ompF up to 50-fold at the posttranscriptional level as determined in strains containing ompF-lacZ operon and protein fusions. Both mutations also decreased norfloxacin accumulation in intact cells. This decrease in accumulation was abolished by energy inhibitors and by removal of the outer membrane. These findings, in conjunction with those of Cohen et al. (S. P. Cohen, D. C. Hooper, J. S. Wolfson, K. S. Souza, L. M. McMurry, and S. B. Levy, Antimicrob. Agents Chemother. 32:1187-1191, 1988), suggest a model for quinolone resistance by decreased permeation in which decreased diffusion through porin channels in the outer membrane interacts with a saturable drug efflux system at the inner membrane.
authors.affiliation: Infectious Disease Unit, Massachusetts General Hospital, Boston 02114.
authors.forename: D C
authors.initials: DC
authors.lastname: Hooper
authors.forename: J S
authors.initials: JS
authors.lastname: Wolfson
authors.forename: K S
authors.initials: KS
authors.lastname: Souza
authors.forename: E Y
authors.initials: EY
authors.lastname: Ng
authors.forename: G L
authors.initials: GL
authors.lastname: McHugh
authors.forename: M N
authors.initials: MN
authors.lastname: Swartz
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology*; D001425:Bacterial Outer Membrane Proteins / Q000096:biosynthesis / Q000235:genetics; D002939:Ciprofloxacin / Q000494:pharmacology; D003227:Conjugation, Genetic; D003470:Culture Media; D004352:Drug Resistance, Microbial / Q000235:genetics; D004734:Energy Metabolism; D004926:Escherichia coli / Q000187:drug effects / Q000235:genetics* / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D008274:Magnesium / Q000378:metabolism; D009154:Mutation; D009643:Norfloxacin / Q000378:metabolism* / Q000494:pharmacology; D013104:Spheroplasts / Q000378:metabolism; D014161:Transduction, Genetic
chemical_list: D000890:Anti-Infective Agents; D001425:Bacterial Outer Membrane Proteins; D003470:Culture Media; D002939:Ciprofloxacin; D008274:Magnesium; D009643:Norfloxacin